Search clinical trials for: lanreotide Autogel (somatostatin analogue)

Total 64 results

Ipsen

Terminated

Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome

Malignant Carcinoid Syndrome

United States
Ipsen

Completed

Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour (NET729)

Non Functioning Entero-pancreatic Endocrine Tumour

United Kingdom, France, Spain, United States, Belgium, Czechia, Italy, Slovakia, Poland
Ipsen

Completed

An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome (ELECT)

Carcinoid Syndrome

United States, Turkey, Brazil, India, Ukraine, South Africa, Czechia, Latvia, Poland, Russian Federation, Serbia
Ipsen

Completed

Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction (IMIO)

Intestinal Obstruction

Belgium
Ipsen

Completed

Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly (LANTERN)

Acromegaly

China
University Medical Center Groningen
Radboud University Medical Center; Erasmus Medical Center; Leiden University...

Unknown

Study of Lanreotide to Treat Polycystic Kidney Disease (DIPAK1)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Netherlands
Sheba Medical Center

Completed

Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy

Congenital Hyperinsulinism

Israel
Ipsen

Terminated

Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours (SPINET)

Neuroendocrine Tumors in Lung

Canada, United States, Germany, France, United Kingdom, Netherlands, Spain, Denmark, Italy, Austria, Poland
Ipsen

Completed

Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours

Neuroendocrine Tumours

Spain
Asan Medical Center
Samsung Medical Center; Seoul St. Mary's Hospital; Seoul National University... and other collaborators

Recruiting

Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs (AIM-NETs)

Neuroendocrine Tumors

Korea, Republic of
Ipsen

Completed

Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs (PALACE)

Gastroenteropancreatic Neuroendocrine Tumor

China
Ipsen

Completed

Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients

Acromegaly

France, Switzerland
University Hospital, Ghent
Ipsen

Completed

Influence of Somatuline Autogel 120mg on Post-operative Drainage After Total Mesorectum Excision for Rectumcarcinoma

Rectal Carcinoma

Belgium
Ipsen

Completed

Somatuline Autogel: Acromegaly Self/Partner Injection Study

Acromegaly

United Kingdom
Ipsen

Completed

Lanreotide Autogel in the Symptomatic Treatment of Refractory Diarrhea (MEDARD)

Diarrhea

Belgium
Ipsen

Completed

Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg (CLARINET FORTE)

Midgut Neuroendocrine Tumours | Pancreatic Tumours

Spain, United Kingdom, Denmark, Belgium, Germany, France, Netherlands, Ireland, Italy, Poland
Ipsen

Completed

Somatuline Autogel Preference and Health Economy Study (SAPHE)

Neuroendocrine Tumour With Carcinoid Symptoms

Denmark, Norway, Sweden
Ipsen

Terminated

Quality of Life in Patients With Inoperable Malignant Bowel Obstruction (QoL in IMBO)

Intestinal Obstruction

Italy
Ipsen

Withdrawn

Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)

Acromegaly

Mexico
Ipsen

Completed

Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel (SALSA)

Acromegaly

United States
Ipsen

Completed

Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects (LEAD)

Acromegaly

France, Brazil, Denmark, Finland, Greece, Korea, Republic of, Latvia, Netherlands, Norway, Poland, Romania, Russian Federation, Serbia, Sweden
Ipsen

Completed

Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma (PRIMARYS)

Acromegaly

Netherlands, Germany, France, United Kingdom, Turkey, Belgium, Czechia, Finland, Italy
Ipsen

Completed

Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly

Acromegaly

United States, Germany, Hong Kong, Czechia, France, Hungary, Netherlands, United Kingdom
Radboud University Medical Center

Unknown

Treatment of the Dumping Syndrome With Lanreotide Autogel®

Dumping Syndrome

Netherlands
Ipsen

Completed

Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients

Acromegaly

Germany, Netherlands, Sweden, Czechia, Denmark, France, Greece, Italy, Spain, United Kingdom
University Hospital, Antwerp
Erasmus Medical Center; ZonMw: The Netherlands Organisation for Health Research... and other collaborators

Recruiting

Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients (SAUNA)

Gastroenteropancreatic Neuroendocrine Tumor

Netherlands, Belgium
Ipsen

Completed

Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours (CLARINET)

Endocrine Tumors

United States, United Kingdom, Netherlands, Belgium, Sweden, Spain, France, Denmark, India, Germany, Austria, Czechia, Italy, Poland, Slovakia
Ipsen

Completed

Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR

Acromegaly

Australia
Federico II University
University of Genova

Completed

Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly (ATG1line)

Acromegaly

Italy
Universitaire Ziekenhuizen KU Leuven
Ipsen

Completed

SOMATULINE Autogel 90 mg IN DUMPING SYNDROME

Dumping Syndrome

Belgium
Universitaire Ziekenhuizen KU Leuven
Ipsen

Completed

Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease (LOCKCYST)

Polycystic Liver Disease

Belgium
Ipsen

Terminated

Predictive Factors Study (TAPAS)

Acromegaly

Australia
University of Aarhus
Aarhus University Hospital; Aarhus University Hospital Skejby; The Research Council...

Completed

Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients

Insulin Resistance | Acromegaly | Impaired Glucose Tolerance

Denmark
Ipsen

Completed

Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly

Acromegaly

Italy
Dana-Farber Cancer Institute
Eli Lilly and Company

Active, not recruiting

A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors

Carcinoid Tumors

United States
Ipsen

Terminated

Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment

Thyroid-Associated Ophthalmopathy

Spain
Odense University Hospital

Completed

Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction

Acromegaly

Denmark
Ipsen

Completed

Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly

Acromegaly

France, Germany, Spain, Belgium, Russian Federation, United Kingdom, Italy, Lithuania, Czechia, Romania, Poland, Netherlands
University Hospital, Limoges
Ipsen

Completed

Prevention of Lymphorrhea by Lanreotide in Axillary Dissection for Breast Cancer

Lymphocele

France
Ipsen

Completed

Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors. (ATLANT)

Neuroendocrine Tumours

Italy
Ipsen

Completed

Somatuline Predictive Factors in Acromegaly and NET (SOPRANo)

Acromegaly | Neuroendocrine Tumours

Switzerland, Austria, Germany
Australasian Gastro-Intestinal Trials Group
Canadian Cancer Trials Group

Not yet recruiting

Cessation of Somatostatin Analogues After PRRT in Mid-Gut Neuroendocrine Tumours (STOPNET)

Neuroendocrine Tumors

Australia
Ipsen

Completed

Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly

Acromegaly

Germany
Ipsen

Completed

Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET (SONNET)

Gastroenteropancreatic Neuroendocrine Tumors

Germany, Austria
Ionis Pharmaceuticals, Inc.

Completed

Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands

Acromegaly

United States, Serbia, Poland, Russian Federation, Hungary, Lithuania
Federico II University
Ospedali dei Colli

Completed

GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma (SS-HCC)

Advanced Hepatocellular Carcinoma

Italy
Medical University of Vienna

Not yet recruiting

Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO Treatment (SANO)

Pancreatic Neuroendocrine Tumors in MEN1
University of Roma La Sapienza

Recruiting

Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN) (REBORN)

Neuroendocrine Tumors | Neuroendocrine Carcinoma | Neuroendocrine Neoplasm | Neuroendocrine Tumor Grade 2 | Neuroendocrine Tumor Grade 1

Italy
University of Aarhus

Unknown

Fatigue and Quality of Life in Patients With Neuroendocrine Neoplasia

Neuroendocrine Tumors (NET) Health Related Qualito of Life (HRQoL)

Denmark
Italfarmaco

Completed

A Two Part Phase 1, Repeated Doses and Continuous Infusion Study With ITF2984 in Healthy Volunteers (14 days MAD)

Healthy

Italy

Search clinical trials for: lanreotide Autogel (somatostatin analogue)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations